MX366651B - Crystal form alpha of compound a monobenzoate and preparation method thereof and pharmaceutical composition comprising same. - Google Patents

Crystal form alpha of compound a monobenzoate and preparation method thereof and pharmaceutical composition comprising same.

Info

Publication number
MX366651B
MX366651B MX2016009667A MX2016009667A MX366651B MX 366651 B MX366651 B MX 366651B MX 2016009667 A MX2016009667 A MX 2016009667A MX 2016009667 A MX2016009667 A MX 2016009667A MX 366651 B MX366651 B MX 366651B
Authority
MX
Mexico
Prior art keywords
crystal form
monobenzoate
compound
preparation
pharmaceutical composition
Prior art date
Application number
MX2016009667A
Other languages
Spanish (es)
Other versions
MX2016009667A (en
Inventor
Li Tongshuang
Tan Songde
Wang Weibo
Original Assignee
Shanghai Fochon Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Fochon Pharmaceutical Co Ltd filed Critical Shanghai Fochon Pharmaceutical Co Ltd
Publication of MX2016009667A publication Critical patent/MX2016009667A/en
Publication of MX366651B publication Critical patent/MX366651B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04—Monocyclic monocarboxylic acids
    • C07C63/06—Benzoic acid
    • C07C63/08—Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

The present invention belongs to the field of preparing pharmaceutical compounds, in particular relates to a crystal form a of compound A monobenzoate, which is a dipeptidase-IV inhibitor, and a preparation method thereof, and a pharmaceutical composition comprising the crystal form.
MX2016009667A 2014-01-24 2015-01-26 Crystal form alpha of compound a monobenzoate and preparation method thereof and pharmaceutical composition comprising same. MX366651B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410037009 2014-01-24
PCT/CN2015/071525 WO2015110077A1 (en) 2014-01-24 2015-01-26 Crystal form α of compound a monobenzoate and preparation method thereof and pharmaceutical composition comprising same

Publications (2)

Publication Number Publication Date
MX2016009667A MX2016009667A (en) 2017-02-28
MX366651B true MX366651B (en) 2019-07-17

Family

ID=53680849

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016009667A MX366651B (en) 2014-01-24 2015-01-26 Crystal form alpha of compound a monobenzoate and preparation method thereof and pharmaceutical composition comprising same.

Country Status (5)

Country Link
CN (1) CN104803971B (en)
BR (1) BR112016017087B1 (en)
MX (1) MX366651B (en)
RU (1) RU2677660C2 (en)
WO (1) WO2015110077A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017008684A1 (en) * 2015-07-15 2017-01-19 深圳信立泰药业股份有限公司 Α-crystal form of compound a, preparation method thereof, and pharmaceutical composition comprising same
CN106349215B (en) * 2015-07-15 2022-02-08 深圳信立泰药业股份有限公司 Amorphous form of compound A benzoate, preparation method thereof and pharmaceutical composition containing amorphous form
WO2018219295A1 (en) * 2017-05-31 2018-12-06 深圳信立泰药业股份有限公司 Deuterated 1,2,4-triazine derivatives of dipeptidyl peptidase iv inhibitor
CN109692164A (en) * 2017-10-20 2019-04-30 深圳信立泰药业股份有限公司 Compound A or the pharmaceutical composition of its salt and preparation method thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006068978A2 (en) * 2004-12-21 2006-06-29 Takeda Pharmaceutial Company Limited Dipeptidyl peptidase inhibitors
TW200745079A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
EP1924567B1 (en) * 2005-09-16 2012-08-22 Takeda Pharmaceutical Company Limited Process for the preparation of pyrimidinedione derivatives
TW200838536A (en) * 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
FR2933979B1 (en) * 2008-07-15 2012-08-24 Pf Medicament TRIAZINE AND URACIL DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY
US8648073B2 (en) * 2009-12-30 2014-02-11 Fochon Pharma, Inc. Certain dipeptidyl peptidase inhibitors
CN103068392A (en) * 2010-05-12 2013-04-24 Mapi医药公司 Polymorphs of alogliptin benzoate
CN103172615A (en) * 2013-03-29 2013-06-26 山东罗欣药业股份有限公司 Benzoic acid alogliptin crystal form compound

Also Published As

Publication number Publication date
WO2015110077A1 (en) 2015-07-30
RU2016134404A3 (en) 2018-08-15
RU2016134404A (en) 2018-03-01
CN104803971B (en) 2021-11-30
MX2016009667A (en) 2017-02-28
BR112016017087A8 (en) 2018-04-17
BR112016017087B1 (en) 2022-12-27
RU2677660C2 (en) 2019-01-18
BR112016017087A2 (en) 2017-08-08
CN104803971A (en) 2015-07-29

Similar Documents

Publication Publication Date Title
MX2017004200A (en) Heteroaryl compounds as btk inhibitors and uses thereof.
AU2015207757A8 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of SHP2
EP3060041A4 (en) Prostacyclin compounds, compositions and methods of use thereof
MX2020001756A (en) Benzoquinolone inhibitors of vmat2.
MX2019015744A (en) Pharmaceutical compositions.
HK1232229A1 (en) Novel compound of 4-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof 4-
MX2018003280A (en) Antifungal compound process.
EP3082819A4 (en) Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
MX2020003139A (en) Composition and method for aiding sleep.
PH12016501122A1 (en) Delayed release compositions of linaclotide
NZ732402A (en) Nitrification inhibitor compositions and methods for preparing the same
EA201691363A1 (en) STABILIZED SILICATE COMPOSITIONS AND THEIR APPLICATION AS ANTI-PERSPIRENT COMPOSITIONS
PH12017500737B1 (en) Kcnq2-5 channel activator
EP3232790A4 (en) Mixotrophic chlorella-based composition, and methods of its preparation and application to plants
MX2014010433A (en) Novel crystalline form of sitagliptin sulfate.
PH12016501865A1 (en) Pyridine-2-amides useful as cb2 agonists
AU2016204294A1 (en) Solid State Forms Of A Quinazoline Derivative And Its Use As A BRAF Inhibitor
CN106687453A8 (en) As the tetrahydroquinoline derivative of bromine domain inhibitor
MX366651B (en) Crystal form alpha of compound a monobenzoate and preparation method thereof and pharmaceutical composition comprising same.
GEP20196974B (en) A novel crystalline form of a benzimidazole derivative and a preparation method thereof
GEP20217236B (en) Composition comprising pentose and polyphenolic compound
MX2015016603A (en) Corticosteroid compositions.
BR112015031820A2 (en) compound, pharmaceutical composition, intermediate, process for preparing a compound and methods
MX2017007931A (en) Novel crystal forms of the monosodium salt of foramsulfuron.
EP3118207A4 (en) Inclusion compound of 3',5'-cyclicdiadenylic acid, and method for producing same

Legal Events

Date Code Title Description
FG Grant or registration